Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Med Clin (Barc) ; 161(11): 463-469, 2023 12 07.
Article in English, Spanish | MEDLINE | ID: mdl-37735046

ABSTRACT

OBJECTIVES: Arterial stiffness is considered to be an intermediate marker with independent prognostic value. The objective of this study is to assess whether the estimation of arterial stiffness can improve CV risk stratification compared to SCORE in patients at community pharmacies. METHODS: Observational prospective epidemiological study in which consecutive individuals entering a participating Community Pharmacy are offered a voluntary measurement of blood pressure and estimation of pulse wave velocity by oscillometry (AGEDIO, IEM®) to stratify their CV risk according to SCORE compared to the use of arterial stiffness. RESULTS: After nine months of recruitment, data from 923 patients (570 women, 353 men) were collected. 16/122 (13.1%) patients under 40 years and 72/364 (19.8%) over 65 years of age presented pathological stiffness and could be classified as high-risk, even though being out of the age-range of SCORE. Of the 437 (47.3%) patients who were susceptible to calculating SCORE, 42/437 patients (9.6%) presented pathological arterial stiffness. Cholesterol values were available in 281 patients (64.3%). Among them, according to SCORE, only 6 (2.1%) fell into the high-risk category. CONCLUSIONS: More than half of the subjects who randomly enter a community pharmacy had ages that make it impossible to calculate the CV risk by SCORE. Among them, arterial damage was detected in 18.1%. Of the other half, 9.6% presented arterial damage and, therefore, high CV risk, when SCORE only detected it in 2.1%. Therefore, estimating arterial stiffness in community pharmacies markedly improves detection of high CV risk compared to SCORE.


Subject(s)
Cardiovascular Diseases , Pharmacies , Vascular Stiffness , Male , Humans , Female , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Prospective Studies , Pulse Wave Analysis , Risk Factors , Blood Pressure , Vascular Stiffness/physiology
2.
J Minim Invasive Gynecol ; 27(5): 1133-1140, 2020.
Article in English | MEDLINE | ID: mdl-32272240

ABSTRACT

STUDY OBJECTIVE: To compare the cost-effectiveness of ultrasound (US)-guided aspiration and ethanol sclerotherapy versus laparoscopic surgery for benign-appearing ovarian endometrioma. DESIGN: Prospective, cohort pilot study. SETTING: Multiple centers, Spain. PATIENTS: Forty patients with suspected ovarian endometrioma identified by US, with a maximum diameter of 35 to 100 mm, of whom 33 met inclusion criteria. INTERVENTIONS: The study group (n = 17) underwent US-guided aspiration plus sclerotherapy with ethanol, and the control group (n = 14) underwent laparoscopic cystectomy. MEASUREMENTS AND MAIN RESULTS: Recurrence, complications, and direct costs were compared. One of 17 sclerotherapy patients recurred (5.9%) compared with 4 of 14 laparoscopic surgery patients (28.6%) (odds ratio 0.18, 0.01-1.53). No serious adverse effects (Clavien-Dindo ≥ III) were observed in the sclerotherapy group; 1 patient in the surgery group had a Clavien-Dindo IIIb complication. Median hospital direct costs were significantly lower in the sclerotherapy group than those in the surgery group-266 euros versus 2189 euros. CONCLUSION: Ethanol sclerotherapy seems to be cost-effective for endometrioma and also appears to reduce complications. In this pilot study, recurrence was not higher than with conventional surgery.


Subject(s)
Endometriosis/therapy , Ethanol/therapeutic use , Laparoscopy/methods , Ovarian Diseases/therapy , Sclerotherapy/methods , Adolescent , Adult , Biopsy, Needle/adverse effects , Biopsy, Needle/economics , Biopsy, Needle/methods , Case-Control Studies , Cohort Studies , Cost-Benefit Analysis , Endometriosis/pathology , Endometriosis/surgery , Female , Humans , Laparoscopy/adverse effects , Laparoscopy/economics , Ovarian Diseases/pathology , Ovarian Diseases/surgery , Pilot Projects , Prospective Studies , Recurrence , Sclerotherapy/adverse effects , Sclerotherapy/economics , Spain , Ultrasonography, Interventional/adverse effects , Ultrasonography, Interventional/economics , Ultrasonography, Interventional/methods , Young Adult
3.
Int J Gynecol Cancer ; 30(1): 83-88, 2020 01.
Article in English | MEDLINE | ID: mdl-31780568

ABSTRACT

INTRODUCTION: The clinical impact on fertility in carriers of BRCA1 and BRCA2 mutations remains unclear. The aim of this study was to assess ovarian reserve as measured by anti-mullerian hormone levels in BRCA1 or BRCA2 mutation carriers, as well as to investigate the impact of anti-mullerian hormone levels on reproductive outcomes. METHODS: The study involved a cohort of women who tested positive for BRCA1 and BRCA2 screening or were tested for a BRCA1 or BRCA2 family mutation. Blood samples were collected for anti-mullerian hormone analysis and the reproductive outcomes were analyzed after a mean follow-up of 9 years. Participants were classified into BRCA mutation-positive versus BRCA mutation-negative. Controls were healthy relatives who tested negative for the family mutation. All patients were contacted by telephone to collect data on reproductive outcomes. Linear regression was used to predict anti-mullerian hormone levels by BRCA status adjusted for a polynomial form of age. RESULTS: Results of anti-mullerian hormone analysis and reproductive outcomes were available for 135 women (BRCA mutation-negative, n=66; BRCA1 mutation-positive, n=32; BRCA2 mutation-positive, n=37). Anti-mullerian hormone curves according to BRCA status and adjusted by age showed that BRCA2 mutation-positive patients have lower levels of anti-mullerian hormone as compared with BRCA-negative and BRCA1 mutation-positive. Among the women who tried to conceive, infertility was observed in 18.7% of BRCA mutation-negative women, in 22.2% of BRCA1 mutation-positive women, and in 30.8% of BRCA2 mutation-positive women (p=0.499). In the multivariable analysis, there were no factors independently associated with infertility. DISCUSSION: BRCA2 mutation-positive carriers showed more diminished anti-mullerian hormone levels than BRCA1 mutation-positive and BRCA mutation-negative women. However, these differences do not appear to have a negative impact on reproductive outcome. This is important to consider at the time of reproductive counseling in women with BRCA1 or BRCA2 mutations.


Subject(s)
BRCA1 Protein/genetics , BRCA2 Protein/genetics , Germ-Line Mutation , Ovarian Reserve/genetics , Reproduction/genetics , Adult , Anti-Mullerian Hormone/blood , Case-Control Studies , Cohort Studies , Female , Fertility/genetics , Genes, BRCA2 , Humans
4.
Int J Cancer ; 145(12): 3194-3206, 2019 12 15.
Article in English | MEDLINE | ID: mdl-31199503

ABSTRACT

Due to the anatomical continuity of the uterine cavity with the cervix, genomic exploitation of material from routine Pap smears and other noninvasive sampling methods represent a unique opportunity to detect signs of disease using biological material shed from the upper genital tract. Recent research findings offer a promising perspective in the detection of endometrial cancer, but certain questions need to be addressed in order to accelerate the implementation of novel technologies in a routine screening or clinical setting. We discuss here new perspectives on detection of endometrial cancer using genomic and other biomarkers in minimally invasive sampling methods with a special focus on public health classic screening criteria, highlighting current gaps in knowledge.


Subject(s)
Endometrial Neoplasms/diagnosis , Biomarkers, Tumor/genetics , Early Detection of Cancer/methods , Endometrial Neoplasms/genetics , Female , Humans , Mass Screening/methods
5.
Cancer Epidemiol ; 61: 129-132, 2019 08.
Article in English | MEDLINE | ID: mdl-31238232

ABSTRACT

INTRODUCTION: The current availability of genomic information represents an opportunity to develop new strategies for early detection of cancer. New molecular tests for endometrial cancer may improve performance and failure rates of histological aspirate-based diagnosis, and provide promising perspectives for a potential screening scenario. However, the selection of relevant biomarkers to develop efficient strategies can be a challenge. MATERIALS AND METHODS: We developed an algorithm to identify the largest number of patients with endometrial cancer using the minimum number of somatic mutations based on The Cancer Genome Atlas (TCGA) dataset. RESULTS: The algorithm provided the number of subjects with mutations (sensitivity) for a given number of biomarkers included in the signature. For instance, by evaluating the 50 most representative point mutations, up to 81.9% of endometrial cancers can be identified in the TCGA dataset. At gene level, a 92.9% sensitivity can be obtained by interrogating five genes. DISCUSSION: We developed a computational method to aid in the selection of relevant genomic biomarkers in endometrial cancer that can be adapted to other cancer types or diseases.


Subject(s)
Early Detection of Cancer/methods , Endometrial Neoplasms/diagnosis , Genomics/methods , Algorithms , Female , Humans , Mutation
SELECTION OF CITATIONS
SEARCH DETAIL
...